ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,346.99
-0.11%
Dow Jones
38,798.99
-0.22%
US Dollar vs MXN
18.4136
0.00%
Brent Oil
79.395
0.00%
Bitcoin
69,480.00
0.21%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Mirum Pharmaceuticals Inc (MIRM)

  7. Mirum Pharmaceuticals Inc (MIRM) Noticias

MIRM Mirum Pharmaceuticals Inc

25.07
0.11 (0.44%)
07 Jun 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Mirum Pharmaceuticals Inc MIRM NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.11 0.44% 25.07 23:00:03
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
24.38 24.07 25.38 25.07 24.96
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
07/6/202417:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/6/202423:04BWLes données à long terme des études LIVMARLI de Mirum sur..
06/6/202415:38EDGAR2Form 8-K - Current report
06/6/202408:30BWLong-Term Data from Mirum’s LIVMARLI Studies in ALGS and..
05/6/202415:05BWMirum Pharmaceuticals to Present at the Goldman Sachs 45th..
31/5/202416:02BWMirum Pharmaceuticals: positive CHMP-Stellungnahme für..
31/5/202412:12BWMirum Pharmaceuticals annonce un avis favorable du CHMP pour..
31/5/202407:30BWMirum Pharmaceuticals Announces Positive CHMP Opinion for..
29/5/202407:30BWLong-Term Data from Mirum’s LIVMARLI Studies in ALGS and..
18/5/202406:00BWMirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN..
16/5/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/5/202418:30BWMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq..
08/5/202415:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/5/202415:04EDGAR2Form 8-K - Current report
08/5/202415:02BWMirum Pharmaceuticals Reports First Quarter 2024 Financial..
07/5/202415:10BWMirum Pharmaceuticals to Present at the Citizens JMP Life..
07/5/202407:30BWMirum Announces Publication of Phase 3 MARCH Data in The..
01/5/202415:10BWMirum Pharmaceuticals to Announce First Quarter 2024..
10/4/202420:30BWMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq..
02/4/202407:30BWMirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution)..
25/3/202406:00GLOBESagimet Biosciences Announces Appointment of Tim Walbert and..
13/3/202417:00BWMirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for..
08/3/202418:30BWMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq..
05/3/202407:00BWMirum Pharmaceuticals to Participate in Upcoming Investor..
29/2/202407:30BWHepatology Publishes Six-Year Data Demonstrating Improved..
28/2/202416:01EDGAR2Form NT 10-K - Notification of inability to timely file Form..
28/2/202415:05EDGAR2Form 8-K - Current report
28/2/202415:03BWMirum Pharmaceuticals Reports Fourth Quarter and Year-End..
21/2/202415:05BWMirum Pharmaceuticals to Announce Fourth Quarter and..
09/2/202420:15BWMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq..
05/2/202420:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202420:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202420:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/1/202418:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/1/202418:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/1/202418:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202420:30BWMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq..
16/1/202415:15EDGAR2Form 8-K - Current report
16/1/202407:30BWMirum Pharmaceuticals Appoints Joanne Quan, MD as Chief..
10/1/202418:00BWMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq..
09/1/202419:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202419:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202419:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202407:30EDGAR2Form 8-K - Current report
08/1/202407:30BWMirum Pharmaceuticals Announces Preliminary Unaudited 2023..
03/1/202407:45BWMirum Pharmaceuticals to Present at the 42nd Annual J.P...
18/12/202315:06EDGAR2Form 8-K - Current report
18/12/202307:30BWMirum Pharmaceuticals Announces Data from EMBARK Phase 2b..
08/12/202318:30BWMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq..
06/12/202316:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Su Consulta Reciente

NASDAQ
MIRM
Mirum Pharmaceuticals
NYSE
BGY
BlackRock Enhanced Inter...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados